bioAffinity Technologies, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
bioAffinity Technologies, Inc. (BIAF) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$185 for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2024-04-01
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2022-12-31 was -$348.40K.
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2022-09-30 was $134.28K.
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2022-06-30 was $0.00.
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2022-03-31 was $213.94K.
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2022 was -$185.00, a 100.03% decline from fiscal 2021.
- bioAffinity Technologies, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $739.60K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | -$348.40K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$214.13K derived: sum of 2 quarters · filed 2024-04-01 | -$214.13K derived: sum of 3 quarters · filed 2024-04-01 | -$185.00 10-K · filed 2024-04-01 | $462.34K 10-K · filed 2023-03-31 |
| 2022-09-30 | $134.28K 10-Q · filed 2023-11-14 | $134.28K derived: sum of 2 quarters · filed 2023-11-14 | $348.22K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $213.94K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $213.94K 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $739.60K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |